SCHEMBL4667474

SCHEMBL4667474

Cc1ccc(S(=O)(=O)N(OC=O)c2ccc(Nc3cc(-c4ccc5c(ccn5CCN5CCCC5)c4)ncn3)cc2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.35
HTR6 P50406 4/20 0.35
BPTF Q12830 4/20 0.34
PAX8 Q06710 1/20 0.34
EGFR P00533 2/20 0.34
SRC P12931 2/20 0.33
ABL1 P00519 2/20 0.33
BCR P11274 2/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
GLA P06280 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4666098 0.96 BPTF (0.35) BACE1HTR6BPTFPAX8SRC
SCHEMBL4664340 0.95 BACE1 (0.35) BACE1BPTFEGFRABL1BCR
SCHEMBL4665810 0.94 ABL1 (0.39) HTR6EGFRABL1BCRTP53
SCHEMBL4666150 0.91 BPTF (0.35) BACE1HTR6BPTFEGFRSRC
SCHEMBL4664038 0.91 EGFR (0.35) BACE1HTR6BPTFEGFRABL1
SCHEMBL4664370 0.90 ABL1 (0.38) HTR6BPTFABL1BCRTP53
SCHEMBL4665744 0.89 MEN1 (0.38) HTR6BPTFEGFRABL1BCR
SCHEMBL4665757 0.89 HTR6 (0.35) HTR6EGFRABL1BCRMEN1
SCHEMBL4667458 0.88 HTR6 (0.41) BACE1HTR6BPTFEGFRABL1
SCHEMBL4666211 0.87 BPTF (0.40) BACE1HTR6BPTFEGFRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors ALTANA PHARMA AG (DE) 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242681-A1 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors MAP3K19, MAP3K6, MAP3K20 BACE1 4299/4885HTR6 826/4885BPTF 2862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.